Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
Amuge, Pauline et al. The lancet. HIV vol. 9,9 (September 2022)
Supporting the health and wellbeing of children and young adults living with HIV
Supporting the health and wellbeing of children and young adults living with HIV
Support our work
Donations to Chiva are used to directly support our work with children and young people living with HIV and their families. Chiva is solely funded through donations, grants and membership income and receives no statutory funding.
Donate